Update on the role of venetoclax and rituximab in the treatment of relapsed or refractory CLL

por D’Rozario, James, Bennett, Samuel K.
Publicado 2019

Inhibition of Pol I Transcription a New Chance in the Fight Against Cancer

por Hein, Nadine, Hannan, Kathrine M., D'Rozario, James, Hannan, Ross
Publicado 2017

A new route for the efficient metalation of unfunctionalized aromatics

por Peel, Andrew J., Tezuka, Noriyuki, D'Rozario, James M., Uchiyama, Masanobu, Wheatley, Andrew E. H.
Publicado 2019

GSTZ1 genotypes correlate with dichloroacetate pharmacokinetics and chronic side effects in multiple myeloma patients in a pilot phase 2 clinical trial

por Tian, Dan Dan, Bennett, Samuel K., Coupland, Lucy A., Forwood, Kathryn, Lwin, Yadanar, Pooryousef, Niloofar, Tea, Illa, Truong, Thy T., Neeman, Teresa, Crispin, Philip, D’Rozario, James, Blackburn, Anneke C.
Publicado 2019

Planned withdrawal of dexamethasone after pomalidomide low-dose dexamethasone induction for lenalidomide-refractory multiple myeloma (ALLG MM14)

por Kalff, Anna, Khong, Tiffany, Ramachandran, Malarmathy, Ho, P Joy, Mollee, Peter, D’Rozario, James, Taylor, Kerry, Estell, Jane, Norton, Sam, Kemp, Roslyn, Mitchell, Andrew J., Reynolds, John, Kennedy, Nola, Quach, Hang, Spencer, Andrew
Publicado 2021

An MRD-stratified pediatric protocol is as deliverable in adolescents and young adults as in children with ALL

por Greenwood, Matthew, Trahair, Toby, Sutton, Rosemary, Osborn, Michael, Kwan, John, Mapp, Sally, Howman, Rebecca, Anazodo, Antoinette, Wylie, Brenton, D’Rozario, James, Hertzberg, Mark, Irving, Ian, Yeung, David, Coyle, Luke, Jager, Amanda, Engeler, Dan, Venn, Nicola, Frampton, Chris, Wei, Andrew H., Bradstock, Kenneth, Dalla-Pozza, Luciano
Publicado 2021

Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab

por Seymour, John F., Kipps, Thomas J., Eichhorst, Barbara F., D’Rozario, James, Owen, Carolyn J., Assouline, Sarit, Lamanna, Nicole, Robak, Tadeusz, de la Serna, Javier, Jaeger, Ulrich, Cartron, Guillaume, Montillo, Marco, Mellink, Clemens, Chyla, Brenda, Panchal, Anesh, Lu, Tong, Wu, Jenny Q., Jiang, Yanwen, Lefebure, Marcus, Boyer, Michelle, Kater, Arnon P.
Publicado 2022

Randomized phase III study (ADMYRE) of plitidepsin in combination with dexamethasone vs. dexamethasone alone in patients with relapsed/refractory multiple myeloma

por Spicka, Ivan, Ocio, Enrique M., Oakervee, Heather E., Greil, Richard, Banh, Raymond H., Huang, Shang-Yi, D’Rozario, James M., Dimopoulos, Meletios A., Martínez, Sara, Extremera, Sonia, Kahatt, Carmen, Alfaro, Vicente, Carella, Angelo M., Meuleman, Nathalie, Hájek, Roman, Symeonidis, Argiris, Min, Chang-Ki, Cannell, Paul, Ludwig, Heinz, Sonneveld, Pieter, Mateos, María Victoria
Publicado 2019

Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study

por Kater, Arnon P., Wu, Jenny Qun, Kipps, Thomas, Eichhorst, Barbara, Hillmen, Peter, D’Rozario, James, Assouline, Sarit, Owen, Carolyn, Robak, Tadeusz, de la Serna, Javier, Jaeger, Ulrich, Cartron, Guillaume, Montillo, Marco, Dubois, Julie, Eldering, Eric, Mellink, Clemens, Van Der Kevie-Kersemaekers, Anne-Marie, Kim, Su Young, Chyla, Brenda, Punnoose, Elizabeth, Bolen, Christopher R., Assaf, Zoe June, Jiang, Yanwen, Wang, Jue, Lefebure, Marcus, Boyer, Michelle, Humphrey, Kathryn, Seymour, John F.
Publicado 2020